Kilitch Drugs (India) Limited
NSE: KILITCH · Pharmaceuticals
Snapshot
Unlock Kilitch Drugs (India) Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Kilitch Drugs (India) Limited is a pharmaceutical company specialising in the development and manufacturing of parenteral, nasal, and oral formulations. Its diverse product portfolio spans therapeutic areas including gastroenterology, oncology, and anti-infectives, alongside nutritional supplements, cosmetics, and herbal products.
Business Model
The company generates revenue through the manufacturing and sale of a wide range of pharmaceutical dosage forms, including injectables, tablets, and topical adhesives. It operates both domestically within India and through export markets.
- Founded:1978
Growth Outlook
Growth is driven by the expansion of its specialised product lines, such as effervescent tablets and topical skin adhesives, alongside its established presence in the injectable and nasal drug markets.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent pharmaceutical manufacturing standards and potential regulatory inspections in both domestic and international markets.
- Market Competition. Intense competition within the generic pharmaceutical sector may exert pressure on pricing and profit margins.
- Export Dependency. Fluctuations in international trade policies and currency exchange rates could impact the profitability of export-oriented operations.
- Product Liability. As a manufacturer of pharmaceutical and healthcare products, the company is exposed to potential legal risks associated with product quality and safety.
Start your research today
Unlock AI insights, financials, peers and live data on Kilitch Drugs (India) Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹237 Cr
TTM · consolidated
NET PROFIT
₹29 Cr
TTM · consolidated
EPS
₹12.54
TTM · consolidated
RETURN ON EQUITY
12.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
15.6%
TTM · consolidated
P/E
17.4×
Q1 FY27 · consolidated
EV/EBITDA
17.7x
Q1 FY27 · consolidated
EBITDA MARGIN
20.2%
TTM · consolidated
NET PROFIT MARGIN
4.4%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.3x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Kilitch Drugs (India) LimitedKILITCH | ₹775 Cr | 17.4× | 17.72 | 14.0% | 20.2% | 12.1% | 15.6% | -36.5% |
WanburyWANBURY | ₹814 Cr | 11.4× | 10.33 | 3.6% | 15.2% | 54.9% | 29.2% | -20.6% |
Bafna Pharmaceuticals LimitedBAFNAPH | ₹796 Cr | 115.1× | 46.63 | -3.1% | 12.5% | 8.6% | 10.3% | +119.3% |
Amanta HealthcarAMANTA | ₹735 Cr | 45.8× | 14.20 | — | 21.5% | 6.7% | 9.9% | +39.7% |
Zim LaboratoriesZIMLAB | ₹715 Cr | 167.1× | 20.79 | 7.6% | 9.9% | 1.3% | 5.7% | +91.2% |
Valiant Laboratories LimitedVALIANTLAB | ₹658 Cr | 42.4× | 19.55 | 89.6% | 11.7% | 5.9% | 8.0% | +50.1% |
As of Q1 FY27
Financials
Kilitch Drugs (India) Limited
NSE: KILITCH · Pharmaceuticals
Snapshot
Unlock Kilitch Drugs (India) Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Kilitch Drugs (India) Limited is a pharmaceutical company specialising in the development and manufacturing of parenteral, nasal, and oral formulations. Its diverse product portfolio spans therapeutic areas including gastroenterology, oncology, and anti-infectives, alongside nutritional supplements, cosmetics, and herbal products.
Business Model
The company generates revenue through the manufacturing and sale of a wide range of pharmaceutical dosage forms, including injectables, tablets, and topical adhesives. It operates both domestically within India and through export markets.
- Founded:1978
Growth Outlook
Growth is driven by the expansion of its specialised product lines, such as effervescent tablets and topical skin adhesives, alongside its established presence in the injectable and nasal drug markets.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent pharmaceutical manufacturing standards and potential regulatory inspections in both domestic and international markets.
- Market Competition. Intense competition within the generic pharmaceutical sector may exert pressure on pricing and profit margins.
- Export Dependency. Fluctuations in international trade policies and currency exchange rates could impact the profitability of export-oriented operations.
- Product Liability. As a manufacturer of pharmaceutical and healthcare products, the company is exposed to potential legal risks associated with product quality and safety.
Start your research today
Unlock AI insights, financials, peers and live data on Kilitch Drugs (India) Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹237 Cr
TTM · consolidated
NET PROFIT
₹29 Cr
TTM · consolidated
EPS
₹12.54
TTM · consolidated
RETURN ON EQUITY
12.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
15.6%
TTM · consolidated
P/E
17.4x
Q1 FY27 · consolidated
EV/EBITDA
17.7x
Q1 FY27 · consolidated
EBITDA MARGIN
20.2%
TTM · consolidated
NET PROFIT MARGIN
4.4%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.3x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27